SLC5A2 solute carrier family 5 member 2
ENSG00000140675 · protein coding · Open Targets profile
Electrogenic Na(+)-coupled sugar symporter that actively transports D-glucose at the plasma membrane, with a Na(+) to sugar coupling ratio of 1:1 (PubMed:20980548, PubMed:28592437, PubMed:34880493, PubMed:37217492, PubMed:38057552). Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump (PubMed:20980548, PubMed:28592437, PubMed:34880493). Unlike SLC5A1/SGLT1, requires the auxiliary protein PDZK1IP1/MAP17 for full transporter activity (PubMed:37217492). Has a primary role in D-glucose reabsorption from glomerular filtrate across the brush border of the early proximal tubules of the kidney (By similarity). {ECO:0000250|UniProtKB:Q923I7, ECO:0000269|PubMed:20980548, ECO:0000269|PubMed:28592437, ECO:0000269|PubMed:34880493, ECO:0000269|PubMed:37217492, ECO:0000269|PubMed:38057552}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
gnomAD loss of function constraint: o/e 0.9709100127220154 (upper bound 1.1898000240325928). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against SLC5A2 (dapagliflozin propanediol, bexagliflozin, ertugliflozin pidolate, ipragliflozin l-proline, ipragliflozin, tofogliflozin, canagliflozin, empagliflozin, ertugliflozin, henagliflozin, canagliflozin anhydrous, tofogliflozin anhydrous), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Kazuoki KondoTanabe Pharma Corporation · 9 of 10 trials Phase 2+
- Nobuya InagakiKyoto University, Graduate School of Medicine · 5 of 6 trials Phase 2+
- Jeffrey TestaniYale University · 3 of 4 trials Phase 2+
- Takashi KadowakiTokyo University · 3 of 3 trials Phase 2+
- Thomas MavrakanasMcGill University Health Centre/Research Institute of the McGill University Health Centre · 3 of 3 trials Phase 2+
- Abinet AkliluYale University · 2 of 2 trials Phase 2+
- Mohamed Abdelhamid AlmeldeinTanta University · 2 of 2 trials Phase 2+
- Reda B BastawisyFaculty of medicine, Kafrelshiekh university · 2 of 2 trials Phase 2+
- Rodolfo Guardado-MendozaUniversidad de Guanajuato · 2 of 2 trials Phase 2+
- Sabyasachi SenWashington DC VA Medical Center · 2 of 2 trials Phase 2+
- Sunita KS SinghUniversity Health Network, Toronto General Hospital · 2 of 2 trials Phase 2+
- Suzanne CraftWake Forest University Health Sciences / Wake Forest School of Medicine · 2 of 2 trials Phase 2+
- Ralph DeFronzoThe University of Texas Health Science Center at San Antonio · 1 of 6 trials Phase 2+
- Nattachai SrisawatChulalongkorn University · 1 of 2 trials Phase 2+
- Abedalrahman DosokyCairo University · 1 of 1 trials Phase 2+
Registry trials of dapagliflozin propanediol, bexagliflozin, ertugliflozin pidolate, ipragliflozin l-proline, ipragliflozin, tofogliflozin, canagliflozin, empagliflozin, ertugliflozin, henagliflozin, canagliflozin anhydrous, tofogliflozin anhydrous updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 341 of 381 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 19 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
85 trials of drugs against SLC5A2 were stopped early; 5 give no reason
Terminated, withdrawn and suspended interventional trials of dapagliflozin propanediol, bexagliflozin, ertugliflozin pidolate, ipragliflozin l-proline, ipragliflozin, tofogliflozin, canagliflozin, empagliflozin, ertugliflozin, henagliflozin, canagliflozin anhydrous, tofogliflozin anhydrous, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 85.
- terminated · 2026-09-25 · AstraZeneca · matched by the registry's drug synonyms“The study was ended earlier than planned due to a sponsor decision.”
- terminated · 2026-06-30 · Washington University School of Medicine · matched by the registry's drug synonyms“Low accrual”
- withdrawn · 2026-06-18 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Empagliflozin“The study was not initiated because the planned prospective design was no longer feasible in routine clinical practice before participant enrollment.”
- terminated · 2026-05-13 · Washington University School of Medicine · Empagliflozin“Futility”
- terminated · 2026-04-16 · Department of Nephrology Clinic Ottakring Vienna · matched by the registry's drug synonyms“Low number of participants”
- terminated · 2026-03-30 · The George Institute · matched by the registry's drug synonyms“The vanguard phase is complete. Further phases did not proceed due to funding constraints. A revised methodology is planned, requiring a new protocol and approvals.”
- terminated · 2026-02-27 · Duke University · Empagliflozin10Mg Tab“The study closed per PI decision due to completion of the biopsy substudy and slow accrual”
- withdrawn · 2026-02-20 · University Hospital, Basel, Switzerland · empagliflozin“Sponsor- Investigator decision”
- terminated · 2026-02-11 · Boston University · matched by the registry's drug synonyms“The study was halted early because of the inability to enroll participants.”
- withdrawn · 2025-12-18 · Eurofarma Laboratorios S.A. · matched by the registry's drug synonyms“Strategic change in development priorities”
- terminated · 2025-12-11 · Jinling Hospital, China · Empagliflozin 10 mg“The patient enrollment rate is proceeding too slowly”
- terminated · 2025-09-24 · AstraZeneca · matched by the registry's drug synonyms“Sponsor Decision”
- terminated · 2025-09-04 · Boehringer Ingelheim · Empagliflozin“Company decision”
- withdrawn · 2025-08-29 · University of California, San Francisco · matched by the registry's drug synonyms“Funding was never secured so clinical trial was never started; this study was abandoned”
- withdrawn · 2025-07-14 · Sadat City University · Empagliflozin 10 MG“Institutional and funding constrains”
- terminated · 2025-06-03 · Medical University of Graz · Ertugliflozin 5 mg“The feasibility (recruitment) of the high number of patients (402 patients with HFrEF or HFmrEF) was impossible due to the rapid increase in SGLT2 inhibitors in patients with heart failure.”
- withdrawn · 2025-03-17 · University of Louisville · matched by the registry's drug synonyms“study withdrawn, no participants enrolled, changes in the study design planned”
- terminated · 2024-12-20 · AstraZeneca · matched by the registry's drug synonyms“The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study.”
- withdrawn · 2024-12-13 · Université de Sherbrooke · Canagliflozin 100mg“end of contract negociations”
- terminated · 2024-12-09 · Kinderkrankenhaus auf der Bult · matched by the registry's drug synonyms“slow recruitment”
- terminated · 2024-11-21 · The George Institute · Comparator monotherapy empagliflozin“Difficulties in recruitment at both sites.”
- terminated · 2024-11-12 · Astellas Pharma Inc · matched by the registry's drug synonyms“Discontinued due to company's strategic reason”
- terminated · 2024-11-08 · Astellas Pharma Korea, Inc. · ipragliflozin“Business decision due to enrollment challenges”
- terminated · 2024-10-09 · Novartis Pharmaceuticals · matched by the registry's drug synonyms“Study was early terminated due to slow recruitment and emerging data showing that prophylactic use of metformin may prevent or reduce the incidence of all-grades alpelisib-related hyperglycemia. The decision was not driven by safety concerns”
- withdrawn · 2024-09-19 · George Medicines PTY Limited · matched by the registry's drug synonyms“The sponsor has determined that this study will be postponed due to changing business priorities.”
Paediatric incentives and obligations for SLC5A2's drugs
For dapagliflozin propanediol, bexagliflozin, ertugliflozin pidolate, ipragliflozin l-proline, ipragliflozin, tofogliflozin, canagliflozin, empagliflozin, ertugliflozin, henagliflozin, canagliflozin anhydrous, tofogliflozin anhydrous: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · SLC5A2 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001841-PIP01-15 (bexagliflozin, Treatment of type II diabetes mellitus): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 15 Jun 2016; EMA/PE/0000241527 (baxdrostat;dapagliflozin propanediol, Prevention of heart failure): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 16 May 2025; EMA/PE/0000230006 (empagliflozin / sitagliptin, Treatment of type 2 diabetes mellitus): W: decision granting a waiver in all age groups for all conditions or indications, 21 Mar 2025; EMEA-003632-PIP01-24 (Empagliflozin / Derivative of 3‐phenyl‐3H,4H,6H,7H‐pyrano[3,4‐d]imidazol‐4‐one (BI 690517), Treatment of heart failure): W: decision granting a waiver in all age groups for all conditions or indications, 13 Sept 2024; +10 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names dapagliflozin propanediol, bexagliflozin, ertugliflozin pidolate, ipragliflozin l-proline, ipragliflozin, tofogliflozin, canagliflozin, empagliflozin, ertugliflozin, henagliflozin, canagliflozin anhydrous, tofogliflozin anhydrousRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Vokanamet: authorised since 23 Apr 2014; Synjardy: authorised since 27 May 2015; Glyxambi: authorised since 11 Nov 2016; Jardiance: authorised since 22 May 2014; +4 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of dapagliflozin propanediol, bexagliflozin, ertugliflozin pidolate, ipragliflozin l-proline, ipragliflozin, tofogliflozin, canagliflozin, empagliflozin, ertugliflozin, henagliflozin, canagliflozin anhydrous, tofogliflozin anhydrousRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 49 interventional studies of dapagliflozin propanediol, bexagliflozin, ertugliflozin pidolate, ipragliflozin l-proline, ipragliflozin, tofogliflozin, canagliflozin, empagliflozin, ertugliflozin, henagliflozin, canagliflozin anhydrous, tofogliflozin anhydrous include patients under 18; 19 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 17 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.